
Gilberto Velho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1826219/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association Between the <i>ACE</i> Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. Diabetes Care, 2022, 45, 407-415.	4.3	3
2	Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes. Cardiovascular Diabetology, 2022, 21, 71.	2.7	2
3	Plasma Adrenomedullin, Allelic Variations in the <i>ADM</i> Gene, and Risk for Lower-Limb Amputation in People With Type 2 Diabetes. Diabetes Care, 2022, 45, 1631-1639.	4.3	1
4	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. Diabetologia, 2021, 64, 668-680.	2.9	12
5	<i>ACE</i> I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. Diabetes Care, 2021, 44, 1377-1384.	4.3	6
6	SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis. Cardiovascular Diabetology, 2021, 20, 107.	2.7	13
7	Adipocyte Reprogramming by the Transcriptional Coregulator GPS2 Impacts Beta Cell Insulin Secretion. Cell Reports, 2020, 32, 108141.	2.9	9
8	Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 2751-2759.	4.3	10
9	Comparison of a new versus standard removable offloading device in patients with neuropathic diabetic foot ulcers: a French national, multicentre, open-label randomized, controlled trial. BMJ Open Diabetes Research and Care, 2020, 8, e000954.	1.2	3
10	Leukocyte Telomere Length, DNA Oxidation, and Risk of Lower-Extremity Amputation in Patients With Long-standing Type 1 Diabetes. Diabetes Care, 2020, 43, 828-834.	4.3	11
11	Plasma Apelin and Risk of Type 2 Diabetes in a Cohort From the Community. Diabetes Care, 2020, 43, e15-e16.	4.3	12
12	Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe <scp>COVID</scp> â€19 in type 2 diabetes. EMBO Molecular Medicine, 2020, 12, e13038.	3.3	48
13	220-OR: Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Risk for Lower Extremity Amputation in People with Type 2 Diabetes. Diabetes, 2020, 69, 220-OR.	0.3	0
14	1799-P: Insulin Secretion during a Graded Glucose Infusion Correlates with GPS2 mRNA Expression in Adipocytes. Diabetes, 2020, 69, 1799-P.	0.3	0
15	Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients. Nephrology Dialysis Transplantation, 2019, 34, 1731-1738.	0.4	9
16	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. Diabetes Care, 2019, 42, 2290-2297.	4.3	15
17	Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia, 2019, 62, 939-947.	2.9	36
18	550-P: Age at Diabetes Onset and Risk for Diabetic Kidney Disease. Diabetes, 2019, 68, 550-P.	0.3	0

#	Article	IF	CITATIONS
19	431-P: Diabetic Retinopathy and Risk of Lower-Extremity Artery Disease in Type 2 Diabetes. Diabetes, 2019, 68, .	0.3	0
20	67-OR: Plasma Copeptin and Risk for Lower Extremity Amputation in People with Type 1 and Type 2 Diabetes. Diabetes, 2019, 68, 67-OR.	0.3	0
21	535-P: Relationship between Renal Capacities to Reabsorb Glucose and Kidney Disease in Patients with Diabetes. Diabetes, 2019, 68, .	0.3	0
22	Nonâ€severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial. Diabetes, Obesity and Metabolism, 2018, 20, 1289-1292.	2.2	15
23	Plasma concentrations of 8-hydroxy-2′-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. Diabetologia, 2018, 61, 977-984.	2.9	28
24	Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study. Diabetologia, 2018, 61, 2643-2653.	2.9	15
25	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovascular Diabetology, 2018, 17, 138.	2.7	104
26	Glucagon revisited: Coordinated actions on the liver and kidney. Diabetes Research and Clinical Practice, 2018, 146, 119-129.	1.1	16
27	Sex Difference In the Effect of Fetal Exposure to Maternal Diabetes on Insulin Secretion. Journal of the Endocrine Society, 2018, 2, 391-397.	0.1	8
28	Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. Cardiovascular Diabetology, 2018, 17, 110.	2.7	35
29	Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes. Diabetes Care, 2018, 41, 2162-2169.	4.3	14
30	Plasma proproteinâ€convertaseâ€subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 943-953.	2.2	17
31	Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population. JCI Insight, 2018, 3, .	2.3	32
32	Association of Diuretics Use and Amputations in Patients with Type 2 Diabetes—A Hypothesis Driven from Canvas Warning?. Diabetes, 2018, 67, .	0.3	2
33	Prognostic Values of Inflammation and Oxidative Stress Biomarkers on the Risk of Peripheral Arterial Disease in Type 2 Diabetes. Diabetes, 2018, 67, 2220-PUB.	0.3	0
34	T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population. Diabetes and Metabolism, 2017, 43, 33-39.	1.4	14
35	Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity. Journal of Diabetes, 2017, 9, 237-242.	0.8	5
36	Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V _{1A} receptors. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E127-E135.	1.8	32

#	Article	IF	CITATIONS
37	Vasopressin and diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2017, 26, 311-318.	1.0	18
38	Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 929-932.	1.2	16
39	T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. Nephrology Dialysis Transplantation, 2017, 32, 1987-1993.	0.4	2
40	Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. Diabetes Care, 2017, 40, 367-374.	4.3	43
41	Vasopressin and metabolic disorders: translation from experimental models to clinical use. Journal of Internal Medicine, 2017, 282, 298-309.	2.7	40
42	Plasma PCSK9 and cardiovascular events in type 2 diabetes. Atherosclerosis, 2017, 263, e81.	0.4	1
43	T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. Nephrology Dialysis Transplantation, 2017, 32, 2144-2144.	0.4	3
44	Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1259-1266.	4.3	38
45	Plasma Copeptin, <i>AVP</i> Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2432-2439.	1.8	58
46	Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes. Diabetes Care, 2016, 39, 2288-2295.	4.3	51
47	The evaluation of offâ€loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale. Journal of Foot and Ankle Research, 2016, 9, 34.	0.7	8
48	Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. Cardiovascular Diabetology, 2016, 15, 5.	2.7	20
49	Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes. Metabolism: Clinical and Experimental, 2016, 65, 12-19.	1.5	37
50	Linkage disequilibrium with HLA-DRB1-DQB1 haplotypes explains the association of TNF-308G>A variant with type 1 diabetes in a Brazilian cohort. Gene, 2015, 568, 50-54.	1.0	6
51	Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study. American Journal of Nephrology, 2015, 42, 107-114.	1.4	43
52	Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 845.	2.7	47
53	Impact of morbid obesity on the kidney function of patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2015, 108, 143-149.	1.1	10
54	Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. Free Radical Biology and Medicine, 2015, 86, 16-24.	1.3	14

#	Article	IF	CITATIONS
55	ABCG8 polymorphisms and renal disease in type 2 diabetic patients. Metabolism: Clinical and Experimental, 2015, 64, 713-719.	1.5	11
56	Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia, 2015, 58, 1081-1090.	2.9	70
57	Plasma Adrenomedullin and Allelic Variation in the <i>ADM</i> Gene and Kidney Disease in People With Type 2 Diabetes. Diabetes, 2015, 64, 3262-3272.	0.3	12
58	Comparison Between Copeptin and Vasopressin in a Population From the Community and in People With Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4656-4663.	1.8	110
59	Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort. Diabetes Care, 2014, 37, 1425-1431.	4.3	65
60	Tissue kallikrein deficiency, insulin resistance, and diabetes in mouse and man. Journal of Endocrinology, 2014, 221, 297-308.	1.2	6
61	Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes. PLoS ONE, 2014, 9, e96916.	1.1	31
62	Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. Diabetologia, 2013, 56, 2733-2742.	2.9	14
63	Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects. Cardiovascular Diabetology, 2013, 12, 119.	2.7	19
64	Angiotensin converting enzyme insertion/deletion polymorphism is associated with increased adiposity and blood pressure in obese children and adolescents. Gene, 2013, 532, 197-202.	1.0	23
65	Allelic variations of the vitamin D receptor (VDR) gene are associated with increased risk of coronary artery disease in type 2 diabetics: The DIABHYCAR prospective study. Diabetes and Metabolism, 2013, 39, 263-270.	1.4	40
66	The lactase persistence genotype is associated with body mass index and dairy consumption in the D.E.S.I.R. study. Metabolism: Clinical and Experimental, 2013, 62, 1323-1329.	1.5	33
67	Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria. Diabetes Care, 2013, 36, 3639-3645.	4.3	73
68	Glucose Metabolism in 105 Children and Adolescents After Pancreatectomy for Congenital Hyperinsulinism. Diabetes Care, 2012, 35, 198-203.	4.3	121
69	Dietary fat intake and polymorphisms at the PPARG locus modulate BMI and type 2 diabetes risk in the D.E.S.I.R. prospective study. International Journal of Obesity, 2012, 36, 218-224.	1.6	51
70	Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in type 2 diabetic subjects. Molecular Genetics and Metabolism, 2012, 106, 359-365.	0.5	36
71	Allelic variations in the vitamin D receptor gene, insulin secretion and parents' heights are independently associated with height in obese children and adolescents. Metabolism: Clinical and Experimental, 2012, 61, 1413-1421.	1.5	25
72	Association of ADIPOQ variants, total and high molecular weight adiponectin levels with coronary artery disease in diabetic and non-diabetic Brazilian subjects. Journal of Diabetes and Its Complications, 2012, 26, 94-98.	1.2	22

#	Article	IF	CITATIONS
73	Allelic variations in superoxide dismutase-1 (SOD1) gene are associated with increased risk of diabetic nephropathy in type 1 diabetic subjects. Molecular Genetics and Metabolism, 2011, 104, 654-660.	0.5	34
74	Two novel mutations in the EIF2AK3 gene in children with Wolcott-Rallison syndrome. Pediatric Diabetes, 2011, 12, 187-191.	1.2	18
75	Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study. Diabetologia, 2011, 54, 554-562.	2.9	28
76	Genetic Variability at the Six Transmembrane Protein of Prostate 2 Locus and the Metabolic Syndrome: The Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2942-2947.	1.8	16
77	Association of common variants in NPPA and NPPB with blood pressure does not translate into kidney damage in a general population study. Journal of Hypertension, 2010, 28, 1230-1233.	0.3	5
78	Glucose Tolerance and Insulin Secretion, Morbidity, and Death in Patients with Cystic Fibrosis. Journal of Pediatrics, 2008, 152, 540-545.e1.	0.9	132
79	The Type and the Position of <i>HNF1A</i> Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3. Diabetes, 2008, 57, 503-508.	0.3	166
80	A standardized protocol to achieve normoglycaemia during labour and delivery in women with typeÂ1 diabetes. Diabetes and Metabolism, 2008, 34, 33-37.	1.4	24
81	Long-Term Follow-Up of Oral Glucose Tolerance Test–Derived Glucose Tolerance and Insulin Secretion and Insulin Sensitivity Indexes in Subjects With Glucokinase Mutations (MODY2). Diabetes Care, 2008, 31, 1321-1323.	4.3	63
82	The Common â^'866G>A Variant in the Promoter of UCP2 Is Associated With Decreased Risk of Coronary Artery Disease in Type 2 Diabetic Men. Diabetes, 2008, 57, 1063-1068.	0.3	44
83	HNF1α mutations are present in half of clinically defined MODY patients in South-Brazilian individuals. Arquivos Brasileiros De Endocrinologia E Metabologia, 2008, 52, 1326-1331.	1.3	14
84	Diagnosis of Hyperglycemia in a Cohort of Brazilian Subjects: Fasting plasma glucose and oral glucose tolerance test based glycemic status are associated with different profiles of insulin sensitivity and insulin secretion. Diabetes Care, 2007, 30, 2135-2137.	4.3	3
85	Adiponectin gene and cardiovascular risk in type 2 diabetic patients: a review of evidences. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 153-159.	1.3	19
86	Genetics of macrovascular complications in diabetes. Current Diabetes Reports, 2006, 6, 162-168.	1.7	11
87	Large Genomic Rearrangements in the Hepatocyte Nuclear Factor-1Â (TCF2) Gene Are the Most Frequent Cause of Maturity-Onset Diabetes of the Young Type 5. Diabetes, 2005, 54, 3126-3132.	0.3	236
88	The Ala45Thr polymorphism of NEUROD1 is associated with type 1 diabetes in Brazilian women. Diabetes and Metabolism, 2005, 31, 599-602.	1.4	6
89	Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome. Biochimie, 2005, 87, 27-32.	1.3	45
90	Diagnosis and Management of Maturity-Onset Diabetes of the Young. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 9-18.	1.8	36

#	Article	IF	CITATIONS
91	The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-? coactivator-1 gene is associated with hypertension in type 2 diabetic men. Diabetologia, 2004, 47, 1980-1983.	2.9	27
92	A polymorphism in the promoter of UCP2 gene modulates lipid levels in patients with type 2 diabetes. Molecular Genetics and Metabolism, 2004, 82, 339-344.	0.5	39
93	Clinical Spectrum Associated with Hepatocyte Nuclear Factor-1β Mutations. Annals of Internal Medicine, 2004, 140, 510.	2.0	308
94	The N363S polymorphism in the glucocorticoid receptor gene is associated with overweight in subjects with type 2 diabetes mellitus. Clinical Endocrinology, 2003, 59, 237-241.	1.2	61
95	Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2Adiabetes. Biochimie, 2003, 85, 1257-1264.	1.3	22
96	Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet, The, 2003, 361, 1861-1865.	6.3	258
97	Maturity-Onset Diabetes of the Young (MODY): Genetic and Clinical Characteristics. Hormone Research in Paediatrics, 2002, 57, 29-33.	0.8	35
98	Variations in the vitamin D-binding protein (Gc locus) and risk of type 2 diabetes mellitus in French Caucasians. Metabolism: Clinical and Experimental, 2001, 50, 366-369.	1.5	38
99	Comments to: Velho G, Hattersley AT, Froguel P (2000) Maternal diabetes alters birth weight in glucokinase-deficient (MODY2) kindred but has no influence on adult weight, height, insulin secretion or insulin sensivity. Diabetologia 43: 1060-1063. Diabetologia, 2001, 44, 516-517.	2.9	0
100	Maturity Onset Diabetes of the Young (Mody). Growth Hormone, 2001, , 79-89.	0.2	4
101	Genetic Determinants of Type 2 Diabetes. Endocrine Reviews, 2001, 56, 91-106.	7.1	60
102	HNF1α controls renal glucose reabsorption in mouse and man. EMBO Reports, 2000, 1, 359-365.	2.0	192
103	Maternal diabetes alters birth weight in glucokinase-deficient (MODY2) kindred but has no influence on adult weight, height, insulin secretion or insulin sensitivity. Diabetologia, 2000, 43, 1060-1063.	2.9	70
104	Association of a variant in exonÂ31 of the sulfonylurea receptorÂ1 (SUR1) gene with typeÂ2 diabetes mellitus in French Caucasians. Human Genetics, 2000, 107, 138-144.	1.8	57
105	Identification of a novel Tru9 I polymorphism in the human vitamin D receptor gene. Journal of Human Genetics, 2000, 45, 56-57.	1.1	43
106	Molecular Genetics of Maturity-onset Diabetes of the Young. Trends in Endocrinology and Metabolism, 1999, 10, 142-146.	3.1	102
107	Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. Diabetologia, 1998, 41, 1017-1023.	2.9	138
108	Missense mutations in the pancreatic islet beta cell inwardly rectifying K + channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia, 1998, 41, 1511-1515.	2.9	254

#	Article	IF	CITATIONS
109	Genetic, metabolic and clinical characteristics of maturity onset diabetes of the young. European Journal of Endocrinology, 1998, 138, 233-239.	1.9	96
110	Leptin Levels, Â-Cell Function, and Insulin Sensitivity in Families with Congenital and Acquired Generalized Lipoatropic Diabetes. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 503-508.	1.8	74
111	An Automated Fluorescent Single-Strand Conformation Polymorphism Technique for Screening Mutations in the Hepatocyte Nuclear Factor-1α Gene (Maturity-Onset Diabetes of the Young). Diabetes, 1997, 46, 2108-2109.	0.3	24
112	Genetic Susceptibility for Human Familial Essential Hypertension in a Region of Homology with Blood Pressure Linkage on Rat Chromosome 10. Human Molecular Genetics, 1997, 6, 2077-2085.	1.4	172
113	Genetic studies of the renin-angiotensin system in arterial hypertension associated with non-insulin-dependent diabetes mellitus. Journal of Hypertension, 1997, 15, 601-606.	0.3	20
114	Identification of nine novel mutations in the hepatocyte nuclear factor 1 alpha gene associated with maturity-onset diabetes of the young (MODY3). Human Molecular Genetics, 1997, 6, 583-586.	1.4	112
115	Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia, 1997, 40, 217-224.	2.9	252
116	Evidence for 100%13C NMR visibility of glucose in human skeletal muscle. Magnetic Resonance in Medicine, 1997, 37, 821-824.	1.9	8
117	Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature, 1996, 384, 455-458.	13.7	1,240
118	A missense mutation in the glucagon receptor gene is associated with non–insulin–dependent diabetes mellitus. Nature Genetics, 1995, 9, 299-304.	9.4	177
119	A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. Nature Genetics, 1995, 9, 418-423.	9.4	205
120	D-Glucose Metabolism in Lymphocytes of Patients with Mitochondrial Point Mutation of the tRNALeu(UUR) Gene. Biochemical and Molecular Medicine, 1995, 54, 91-95.	1.5	1
121	Maturity-onset diabetes of the young. Current Opinion in Pediatrics, 1994, 6, 482-485.	1.0	7
122	Non-sense mutation of glucokinase gene. Lancet, The, 1993, 341, 385-386.	6.3	7
123	Familial Hyperglycemia Due to Mutations in Glucokinase Definition of a Subtype of Diabetes Mellitus. New England Journal of Medicine, 1993, 328, 697-702.	13.9	721
124	Insulin receptor substrate (IRS-1) gene polymorphisms in French NIDDM families. Lancet, The, 1993, 342, 1430.	6.3	84
125	Polymorphism of the Glycogen Synthase Gene and Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1993, 328, 1568-1569.	13.9	42
126	Beta-cell secretory defect caused by mutations in glucokinase gene. Lancet, The, 1992, 340, 1162-1163.	6.3	11

#	Article	IF	CITATIONS
127	Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet, The, 1992, 340, 444-448.	6.3	228
128	Evaluating in vitro and in vivo the interference of ascorbate and acetaminophen on glucose detection by a needle-type glucose sensor. Biosensors and Bioelectronics, 1992, 7, 345-352.	5.3	65
129	Strategies for the collection of sibling-pair data for genetic studies in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1991, 34, 685-685.	2.9	16
130	Two Taql RFLPs at the GLUT2 locus in French Caucasian population. Nucleic Acids Research, 1991, 19, 5799-5799.	6.5	3
131	CA repeat polymorphism in the glucose transporter GLUT 2 gene. Nucleic Acids Research, 1991, 19, 3754-3754.	6.5	6
132	Study and development of multilayer needle-type enzyme-based glucose microsensors. Biosensors, 1989, 4, 27-40.	2.0	33
133	Determination of peritoneal glucose kinetics in rats: implications for the peritoneal implantation of closed-loop insulin delivery systems. Diabetologia, 1989, 32, 331-336.	2.9	25
134	Absence of Effect of Heparin on Insulin Secretion. Artificial Organs, 1988, 12, 137-142.	1.0	7
135	Type 2 Diabetes: Genetic Factors. , 0, , 141-153.		2